ProCE Banner Activity

CE / CME

The X Factor: Following the Science to Confront MDR, DTR, and XDR Gram-Negative Infections

Video

In this on-demand webcast, learn from experts about the clinical guidance recommendations and recent clinical findings on strategies to optimize antimicrobial regimens for patients with complex clinical infections involving gram-negative resistance.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: November 17, 2023

Expiration: November 16, 2024

No longer available for credit.

Share

Faculty

Emily Heil

Emily Heil, PharmD, MS, BCIDP, AAHIVP

Associate Professor
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Trevor Van Schooneveld

Trevor Van Schooneveld, MD, FSHEA, FACP

Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska 

Laila Woc-Colburn

Laila Woc-Colburn, MD

Associate Professor
Divsion of Infectious Disesases
Emory University School of Medicine
Emory Healthcare
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc.

Target Audience

The intended audience for this educational initiative is physicians, pharmacists, and other healthcare professionals who care for patients with antimicrobial resistant gram-negative infections.

Program Learning Goal

The goal of this activity is to enable learners to optimize antimicrobial strategies for patients with complex clinical infections involving MDR, DTR, and XDR gram-negative organisms.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply the latest data on AMR patterns and mechanisms into diagnostic and therapeutic approaches for AMR gram-negative infections

  • Optimize newer broad-spectrum antimicrobial agents in the treatment of infections caused by MDR, DTR, and XDR gram-negative organisms

  • Integrate up-to-date scientific data and clinical recommendations into timely treatment plans for complex AMR infections involving critically ill patients and XDROs

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Trevor Van Schooneveld, MD, FSHEA, FACP

Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska 

Trevor Van Schooneveld, MD, FSHEA, FACPconsultant/advisor/speaker: bioMérieux, Thermo Fisher; researcher: AN2 Therapeutics, Insmed.

Primary Author

Emily Heil, PharmD, MS, BCIDP, AAHIVP

Associate Professor
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Emily Heil, PharmD, MS, BCIDP, AAHIVP, no relevant financial relationships to disclose.

Laila Woc-Colburn, MD

Associate Professor
Divsion of Infectious Disesases
Emory University School of Medicine
Emory Healthcare
Atlanta, Georgia

Laila Woc-Colburn, MD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 17, 2023, through November 16, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of 65 or better and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 



Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008176-0000-23-301-H01-P 
Type of Activity: Application 

Upon successfully completing the post-test with a score of 65 and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.